uniQure N.V. (QURE) is gaining bullish attention for its pioneering AMT-130 gene therapy, which some observers view as a groundbreaking approach to Huntington’s disease. With shares trading at $63.65 and a forward P/E of 27.93, investors see promise in the biotech’s innovative push toward a first-of-its-kind treatment.